NasdaqGS:TYRABiotechs
Tyra Biosciences (TYRA) Is Up 12.7% After Wedbush Highlights Pipeline Momentum And Leadership Refresh - What's Changed
In December 2025, Wedbush highlighted Tyra Biosciences’ advancing clinical pipeline, pointing to upcoming Phase 2 data in 2026 and a planned Phase 2 trial in upper tract urothelial carcinoma, while the company refreshed its leadership with new chief operating and regulatory officers.
The combination of maturing late-stage programs and strengthened executive oversight underscores how Tyra is positioning itself to potentially move targeted therapies to market more efficiently.
We’ll now...